Country Report · Asia Edition · 2026

From Factory
to Founder

Singapore has spent two decades becoming Asia’s biopharma factory floor. Now, with a unicorn on the board and its first home-grown gene therapy heading to the clinic, the question is whether it can learn to invent — not just manufacture.

Download the report → Explore the story
Ankit Kankar
Ankit Kankar
Chief Operating Officer, BioSpectrum Asia
0
of the world’s top biopharma firms manufacture here
0
2023 biopharma output, double two decades earlier
0
biopharma manufacturing plants on the island
0
manufacturing professionals (+55% in a decade)
The pivot

One lens runs through the whole report

We read the market by where it sits on the value chain — and the bet it’s making to move up. Tap a stage to see where Singapore stands today.

The pivot question: what bet is Singapore making to climb the chain — and is it working?
Inside the report

Seven beats, one question

A 4,000-word analysis, told in seven sections. Browse the argument, then download the full report for the sourcing and detail.

The modality bets

Where the money is going

Three advanced modalities show Singapore concentrating at the high-value, high-difficulty end. Tap each to expand.

The three bets at a glance
Modality Maturity
in Singapore		 Capital
intensity		 Home-grown
ownership
More filled dots = higher. Source: BioSpectrum Asia analysis of EDB, A*STAR and company disclosures.
By the numbers

A deliberate, well-funded bet

Raising the bet · five-year science plan
S$28B
RIE2025
S$37B
RIE2030
RIE2030 lifts the commitment to S$37B. Source: EDB; Bain.
Output doubled · biopharma manufacturing
~S$9B
2003
S$18.7B
2023
Roughly doubled over two decades. Source: A*STAR, EDB.
The competition · China’s rising share
~33% TODAY
~33% today
40% by 2026
Share of big pharma’s external assets sourced from China. Source: EDB.
The home-grown story

The founders have arrived

Real companies, owning their science and carrying it to global markets — the proof the pivot is producing.

Outlook

What to watch · 2026–2029

  • Nuevocor’s first-in-human trial begins (early 2026) — proof Singapore can originate, not only make.
  • AstraZeneca’s ADC site builds toward 2029 operational readiness.
  • First locally manufactured cell therapies move through ACTRIS into approved use.
  • NATi and the mRNA programme translate ambition into clinical pipelines.
  • Exits, repeat founders, and MNC R&D mandates — the structural signs of a maturing ecosystem.
Free · 8 pages Report cover

Get the full report free

  • The full factory-to-founder analysis, sourced throughout
  • Investment, funding and competition data visuals
  • Profiles of MiRXES, Nuevocor and SCG Cell Therapy
  • The modality matrix and 2026–2029 watchlist
Please enter your first name.
Please enter your last name.
Please enter a valid work email.
Please enter your company.
Please enter your job title.
Please select your country.
We respect your inbox. No spam — just the report and the occasional Country Report release.
✓

Your report is downloading

Thanks — enjoy the read. If the download didn’t start automatically, use the button below.

Download the PDF ↓